A study on the effect of improving the QOL (quality of life), response and safety of eribulin mesylate for inoperable or recurrent breast cancer
Not Applicable
Recruiting
- Conditions
- inoperable or recurrent breast cancer
- Registration Number
- JPRN-UMIN000010807
- Lead Sponsor
- Department of Breast Surgery, Nippon Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
- patients with advanced bone marrow suppression. - patients who has an anamnesis of hypersensitivity to the ingredient of this agent. - pregnant women or the women that may have become pregnant - patients simultaneously treatmented by trastuzumab or lapatinib. - patients who judged that it was unsuitable as other candidates
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The effect of improving the QOL(Quality of life) evaluated by the FACT-B
- Secondary Outcome Measures
Name Time Method - OSS (objective response rate) evaluate by RECIST - Safety